For the Use of a Registered Medical Practitioner Only

PRESCRIBING INFORMATION

LEVIPIL

(Levetiracetam Concentrate for Solution for Infusion USP 100 mg/ml, 5 ml)

COMPOSITION

Each ml contains
Levetiracetam USP ……..100 mg

Excipients*:* Sodium chloride, Sodium acetate Trihydrate, Glacial acetic acid, Water for injection

DESCRIPTION

Levetiracetam Concentrate for solution for infusion USP 100 mg/ml, 5 ml is a clear colorless solution filled in 5ml tubular colorless glass vial sealed with light green color flip off Aluminium seal.

After dilution:

Clear and colorless solution free from visible particulate matter.

INDICATIONS

Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in adults and adolescents from 16 years of age with newly diagnosed epilepsy.

Levetiracetam is indicated as adjunctive therapy in the treatment of:

- Partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
- Myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.
- Primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Levetiracetam injection is an alternative for patients (adults and children from 4 years of age) when oral administration is temporarily not feasible.

DOSE AND METHOD OF ADMINISTRATION

Levetiracetam therapy can be initiated with either intravenous or oral administration. Conversion to or from oral to intravenous administration can be done directly without titration. The total daily dose and frequency of administration should be maintained.

Levetiracetam concentrate is an alternative for patients (adults and children from 4 years of age) when oral administration is temporarily not feasible.

Adults

- Monotherapy

Adults and adolescents from 16 years of age

The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily.

- Add-on therapy

Adults (≥18 years) and adolescents (12 to 17 years) of 50 kg or more

The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment.

Depending upon the clinical response and tolerance, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decreases every two to four weeks.

Children

The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age, weight and dose.

The safety and efficacy of levetiracetam concentrate for solution for infusion in infants and children less than 4 years have not been established.

Monotherapy

The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been reported.

There are no data available.

Add-on Therapy

Add-on therapy for children (4 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg
Levetiracetam oral solution is the preferred formulation for use in children under the age of 6 years.

The initial therapeutic dose is 10 mg/kg twice daily.

Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg/kg twice daily. Dose changes should not exceed increases or decreases of 10 mg/kg twice daily every two weeks.

The lowest effective dose should be used.
Dose in children 50 kg or greater is the same as in adults.

Table: Dose recommendations for children and adolescents:

Weight	**Starting dose** **10 mg/kg twice daily**	**Maximum dose** **30 mg/kg twice daily**
10 kg[1]	100 mg twice daily	300 mg twice daily
15 kg[1]	150 mg twice daily	450 mg twice daily
20 kg[1]	200 mg twice daily	600 mg twice daily
25 kg	250 mg twice daily	750 mg twice daily
From 50 kg[2]	500 mg twice daily	1500 mg twice daily

[1] Children 25 kg or less should preferably start the treatment with Levetiracetam 100 mg/ml oral solution
[2] Dose in children and adolescents 50 kg or more is the same as in adults

Elderly
Adjustment of the dose is recommended in elderly patients with compromised renal function.

Renal impairment
The daily dose must be individualised according to renal function (see **WARNINGS AND PRECAUTIONS**). For adult patients, refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient's creatinine clearance (CL_{cr}) in ml/min is needed. The CL_{cr} in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighing 50 kg or more, using the following formula:

$$CL_{cr} = \frac{[140\text{-age (years)}] \times \text{weight (kg)}}{72 \times \text{serum creatinine (mg/dl)}} \quad (\times 0.85 \text{ for women})$$

Then CL_{cr} is adjusted for body surface area (BSA) as follows:

$$CL_{cr}\ (\text{ml/min})$$

CL_{cr} (ml/min/1.73m^2)= ---------- x 1.73

BSA subject (m^2)

Table: Dosing adjustment for adult and adolescent patients weighing more than 50 kg with impaired renal function

Group	Creatinine clearance (ml/min/1.73m^2)	Dosage and frequency
Normal	>80	500 to 1500 mg twice daily
Mild	50-79	500 to 1000 mg twice daily
Moderate	30-49	250 to 750 mg twice daily
Severe	<30	250 to 500 mg twice daily
End-stage renal disease patients undergoing dialysis(1)	-	500 to 1000 mg once daily(2)

(1) A 750 mg loading dose is recommended on the first day of treatment with levetiracetam.

(2) Following dialysis, a 250 to 500 mg supplemental dose is recommended.

For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function. This recommendation is based on a study in adult renally impaired patients.

The CL_{cr} in ml/min/1.73 m^2 may be estimated from serum creatinine (mg/dl) determination using, for young adolescents and children using the following formula (Schwartz formula):

Height (cm) x ks

CL_{cr} (ml/min/1.73 m^2) = ----------

Serum Creatinine (mg/dl)

ks = 0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in adolescent male

Dosing adjustment for children and adolescents patients weighing less than 50 kg with impaired renal function.

Group	Creatinine clearance (ml/min/1.73m^2)	Children and adolescents weighing less than 50 kg
Normal	> 80	10 to 30 mg/kg (0.10 to 0.30 ml/kg) twice daily
Mild	50-79	10 to 20 mg/kg (0.10 to 0.20 ml/kg) twice daily
Moderate	30-49	5 to 15 mg/kg (0.05 to 0.15 ml/kg) twice daily
Severe	< 30	5 to 10 mg/kg (0.05 to 0.10 ml/kg) twice daily
End-stage renal disease patients undergoing dialysis	-	10 to 20 mg/kg (0.10 to 0.20 ml/kg)once daily (1) (2)

(1) A 15 mg/kg (0.15 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.

(2) Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended.

Hepatic impairment

No dose adjustment is needed in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency. Therefore a 50% reduction of the daily maintenance dose is recommended when the creatinine clearance is <60 ml/min/1.73m^2 (see **WARNINGS AND PRECAUTIONS**).

CONTRAINDICATIONS

- Hypersensitivity to levetiracetam or other pyrrolidone derivatives or to any of the excipients.

WARNINGS AND PRECAUTIONS

Discontinuation

If levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in children and adolescents weighing less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks).

Renal or hepatic impairment

The administration of levetiracetam to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection.

Acute Kidney Injury

The use of levetiracetam has been very rarely associated with acute kidney injury, with a time to onset ranging from a few days to several months.

Blood cell counts

Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders (see **UNDESIRABLE EFFECTS**).

Depression and/or suicidal ideation

Suicide, suicide attempt and suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A small increased risk of suicidal thoughts and behavior have been reported. The mechanism of this risk is not known. Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be

considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.

Paediatric population

Available information in children did not suggest impact on growth and puberty. However, long-term effects on learning, intelligence, growth, endocrine function, puberty and child bearing potential in children remain unknown.

Effects on Ability to Drive and Use Machine

Levetiracetam has minor or moderate influence on the ability to drive and use machines. Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, at the beginning of treatment or following a dose increase. Therefore, caution is recommended in those patients when performing skilled tasks, e.g. driving vehicles or operating machinery. Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected.

Sodium

This medicinal product contains 2.5 mmol (or 57 mg) sodium per maximum single dose (0.83 mmol (or 19 mg) per vial). It should be taken into consideration by patients on a controlled sodium diet

USE IN SPECIAL POPULATIONS

Fertility

No impact on fertility was reported in animals. No clinical data are available, potential risk for human is unknown.

Pregnancy

Levetiracetam is not recommended during pregnancy and in women of childbearing potential not using contraception unless clearly necessary.

A substantial increase in the risk for major congenital malformations has not been reported in pregnant women, although a teratogenic risk cannot be completely excluded. Therapy with multiple antiepileptic medicinal products is associated with a higher risk of congenital malformations than monotherapy and, therefore, monotherapy should be considered. Reproductive toxicity have been reported in animals.

Physiological changes during pregnancy may affect levetiracetam concentration. Decrease in levetiracetam plasma concentrations has been reported during pregnancy. This decrease is more pronounced during the third trimester (up to 60% of baseline concentration before pregnancy). Appropriate clinical management of pregnant women treated with levetiracetam should be ensured.

Discontinuation of anti-epileptic treatments may result in exacerbation of the disease which could be harmful to the mother and the foetus.

Lactation

Levetiracetam is reported to be excreted in human breast milk. Therefore, breast-feeding is not recommended. However, if levetiracetam treatment is needed during breast-feeding, the benefit/risk of the treatment should be weighed considering the importance of breast-feeding.

DRUG INTERACTIONS

Anti-epileptic medicinal products

Levetiracetam did not influence the serum concentrations of existing anti-epileptic medicinal products (phenytoin, carbamazepine, Valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these anti-epileptic medicinal products did not influence the pharmacokinetics of levetiracetam.

As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day levetiracetam.

Adjunctive therapy with levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate. However, data suggested a higher levetiracetam clearance in children taking enzyme-inducing anti-epileptic medicinal products. Dose adjustment is not required.

Probenecid

Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been reported to inhibit the renal clearance of the primary metabolite but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.

Methotrexate

Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.

Oral contraceptives, digoxin and warfarin

Levetiracetam 1000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters (luteinising hormone and progesterone) were not modified. Levetiracetam 2000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified. Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.

Laxatives

There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.

Food and alcohol

The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced.

No data on the interaction of levetiracetam with alcohol have been reported.

UNDESIRABLE EFFECTS

Summary of the safety profile

The most frequently reported adverse reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness. The safety profile of levetiracetam is generally reported to be similar across age groups (adult and paediatric patients) and across the approved epilepsy indications.

Infections and infestations

Very Common: nasopharyngitis
Rare: infection

Blood and lymphatic system disorders

Uncommon: thrombocytopenia, leukopenia
Rare: pancytopenia, neutropenia, agranulocytosis

Immune system disorders

Rare: drug reaction with eosinophilia and systemic symptoms (DRESS), hypersensitivity (including angioedema and anaphylaxis)

Metabolism and nutrition disorders

Common: anorexia
Uncommon: weight decreased, weight increase
Rare: hyponatraemia

Psychiatric disorders

Common: depression, hostility/aggression, anxiety, insomnia, nervousness/irritability
Uncommon: suicide attempt, suicidal ideation, psychotic disorder, abnormal behaviour, hallucination, anger, confusional state, panic attack, affect lability/mood swings, agitation
Rare: completed suicide, personality disorder, thinking abnormal

Nervous system disorders
Very common: somnolence, headache
Common: convulsion, balance disorder, dizziness, lethargy, tremor
Uncommon: amnesia, memory impairment, coordination abnormal/ataxia, paraesthesia, disturbance in attention
Rare: choreoathetosis, dyskinesia, hyperkinesia

Eye disorders
Uncommon: diplopia, vision blurred

Ear and labyrinth disorders
Common: vertigo

Respiratory, thoracic and mediastinal disorders
Common: cough

Gastrointestinal disorders
Common: abdominal pain, diarrhoea, dyspepsia, vomiting, nausea
Rare: pancreatitis

Hepatobiliary disorders
Uncommon: liver function test abnormal
Rare: hepatic failure, hepatitis

Renal and urinary disorders
Rare: acute kidney injury

Skin and subcutaneous tissue disorders
Common: rash
Uncommon: alopecia, eczema, pruritus
Rare: toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme

Musculoskeletal and connective tissue disorders
Uncommon: muscular weakness, myalgia
Rare: rhabdomyolysis and blood creatine phosphokinase increased*

General disorders and administration site conditions
Common: asthenia/fatigue

Injury, poisoning and procedural complications
Uncommon: injury

*Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.

Cases of encephalopathy have been rarely reported after levetiracetam administration. These undesirable effects generally reported at the beginning of the treatment (few days to a few months) and were reversible after treatment discontinuation.

Description of selected adverse reactions
The risk of anorexia is higher when levetiracetam is co-administered with topiramate.

In several cases of alopecia, recovery was reported when levetiracetam was discontinued.

Bone marrow suppression was reported in some of the cases of pancytopenia.

Paediatric population
The adverse event profile of levetiracetam is generally reported to be similar across age groups and across the approved epilepsy indications. Safety results in paediatric patients were consistent with the safety profile of levetiracetam in adults except for behavioural and psychiatric adverse reactions which were more common in children than in adults. In children and adolescents aged 4 to 16 years, vomiting, agitation, mood swings, affect lability, aggression, abnormal behavior, and lethargy were reported more frequently than in other age ranges or in the overall safety profile. In infants and children aged 1 month to less than 4 years, irritability and coordination abnormal were reported more frequently than in other age groups or in the overall safety profile.

OVERDOSE

Symptoms and signs
Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were reported with levetiracetam overdoses.

Management of overdose
There is no specific antidote for levetiracetam. Treatment of an overdose will be symptomatic and may include haemodialysis. The dialyser extraction efficiency is 60% for levetiracetam and 74% for the primary metabolite.

Further management should be as clinically indicated or as recommended by the national poisons centre, where available.

PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES

Pharmacodynamics

Pharmacotherapeutic group
Antiepileptics, Other Antiepileptics

ATC code: N03AX14.

Mechanism of action

The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of α-ethyl-2-oxo-1-pyrrolidine acetamide), chemically unrelated to existing anti-epileptic active substances.

The mechanism of action of levetiracetam still remains to be fully elucidated. Levetiracetam does not alter basic cell characteristics and normal neurotransmission.

Levetiracetam affects intraneuronal Ca^{2+} levels by partial inhibition of N-type Ca^{2+} currents and by reducing the release of Ca^{2+} from intraneuronal stores. In addition it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β-carbolines. Furthermore, levetiracetam has been reported to bind to a specific site in rodent brain tissue. This binding site is the synaptic vesicle protein 2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis. Levetiracetam and related analogs show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. This finding suggests that the interaction between levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product.

Pharmacodynamic effects

Levetiracetam induces seizure protection in a broad range of animal models of partial and primarily generalised seizures without having a pro-convulsant effect. The primary metabolite is inactive. In man, activity in both partial and generalised epilepsy conditions (epileptiform discharge/photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of levetiracetam.

Pharmacokinetics

Levetiracetam is a highly soluble and permeable compound. The pharmacokinetic profile is reported to be linear with low intra- and inter-subject variability. There is no modification of the clearance after repeated administration. The time independent pharmacokinetic profile of levetiracetam was also confirmed following 1500 mg intravenous infusion for 4 days with twice daily dosing.

There is no reported evidence for any relevant gender, race or circadian variability. The pharmacokinetic profile is comparable in healthy subjects and in patients with epilepsy.

Due to its complete and linear absorption, plasma levels can be predicted from the oral dose of levetiracetam expressed as mg/kg bodyweight. Therefore there is no need for plasma level monitoring of levetiracetam.

A significant correlation between saliva and plasma concentrations has been reported in adults and children (ratio of saliva/plasma concentrations ranged from 1 to 1.7 for oral tablet formulation and after 4 hours post-dose for oral solution formulation).

The pharmacokinetic profile has been characterised following oral administration. A single dose of 1500 mg levetiracetam diluted in 100 ml of a compatible diluent and infused intravenously over 15 minutes is bioequivalent to 1500 mg levetiracetam oral intake, given as three 500 mg tablets.

The intravenous administration of doses up to 4000 mg diluted in 100 ml of 0.9% sodium chloride infused over 15 minutes and doses up to 2500 mg diluted in 100 ml of 0.9% sodium chloride infused over 5 minutes was evaluated. The pharmacokinetic and safety profiles did not identify any safety concerns.

Absorption

Levetiracetam is reported to be rapidly absorbed after oral administration. Oral absolute bioavailability is close to 100%. Peak plasma concentrations (C_{max}) are reported at 1.3 hours after dosing. Steady-state is reported after two days of a twice daily administration schedule. Peak concentrations (C_{max}) are typically reported as 31 and 43 µg/ml following a single 1000 mg dose and repeated 1000 mg twice daily dose, respectively. The extent of absorption is dose-independent and is not altered by food.

Distribution

No tissue distribution data are available. Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins. The volume of distribution of levetiracetam is approximately 0.5 to 0.7 l/kg, a value close to the total body water volume.

Peak plasma concentration (C_{max}) reported following a single intravenous dose of 1500 mg infused over 15 minutes was 51 ± 19 µg/mL (arithmetic average ± standard deviation).

Metabolism

Levetiracetam is not extensively metabolised in humans. The major metabolic pathway is an enzymatic hydrolysis of the acetamide group. Production of the primary metabolite, ucb L057, is not supported by liver cytochrome P450 isoforms. Hydrolysis of the acetamide group was measurable in a large number of tissues including blood cells. The metabolite ucb L057 is pharmacologically inactive.

Two minor metabolites were also identified. One was obtained by hydroxylation of the pyrrolidone ring and the other one by opening of the pyrrolidone ring.

Other unidentified components accounted only for 0.6% of the dose.

No enantiomeric interconversion was evidenced for either levetiracetam or its primary metabolite.

Levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 and UGT1A6) and epoxide hydroxylase activities. In addition, levetiracetam does not affect the *in vitro* glucuronidation of valproic acid.

Levetiracetam had little or no effect on CYP1A12, SULT1E1 or UGT1A1. Levetiracetam caused mild induction of CYP2B6 and CYP3A4. Interaction data on oral contraceptives, digoxin and warfarin indicate that no significant enzyme induction is expected. Therefore, the interaction of levetiracetam with other substances, or vice versa, is unlikely.

Elimination

The plasma half-life in adults was reported to be 7±1 hours and did not vary either with dose, route of administration or repeated administration. The mean total body clearance was 0.96 ml/min/kg.

The major route of excretion was via urine, accounting for a mean 95% of the dose (approximately 93% of the dose was excreted within 48 hours). Excretion via faeces accounted for only 0.3% of the dose.

The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66% and 24% of the dose, respectively during the first 48 hours. The renal clearance of levetiracetam and ucb L057 is 0.6 and 4.2 ml/min/kg respectively indicating that levetiracetam is excreted by glomerular filtration with subsequent tubular reabsorption and that the primary metabolite is also excreted by active tubular secretion in addition to glomerular filtration. Levetiracetam elimination is correlated to creatinine clearance.

Special patient populations

Children (4 to 12 years)

Following single dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was reported to be 6.0 hours. The apparent body weight adjusted clearance was approximately 30% higher than in epileptic adults.

Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years), levetiracetam was rapidly absorbed. Peak plasma concentration was reported 0.5 to 1.0 hour after dosing. Linear and dose proportional increases were reported for peak plasma concentrations and area under the curve. The elimination half-life was approximately 5 hours. The apparent body clearance was 1.1 ml/min/kg.

Elderly

In the elderly, the half-life is reported to be increased by about 40% (10 to 11 hours). This is related to the decrease in renal function in this population.

Renal impairment

The apparent body clearance of both levetiracetam and of its primary metabolite is correlated to the creatinine clearance. It is therefore recommended to adjust the maintenance daily dose of levetiracetam, based on creatinine clearance in patients with moderate and severe renal impairment.

In anuric end-stage renal disease subjects, the half-life was reported to be approximately 25 and 3.1 hours during interdialytic and intradialytic periods, respectively.

The fractional removal of levetiracetam was 51% during a typical 4-hour dialysis session.

Hepatic impairment

In subjects with mild and moderate hepatic impairment, no relevant modification of the clearance of levetiracetam has been reported. In most subjects with severe hepatic impairment, the clearance of levetiracetam has been reported to reduce by more than 50% due to a concomitant renal impairment.

Incompatibilities and Use and Handling

Levetiracetam injection is for intravenous use only and the recommended dose must be diluted in at least 100 ml of a compatible diluent and administered intravenously as 15-minute intravenous infusion. There is no experience with administration of intravenous levetiracetam for longer period than 4 days

Levetiracetam Concentrate for Solution for Infusion 100 mg/ml

Table presents the recommended preparation and administration of levetiracetam concentrate to achieve a total daily dose of 500 mg, 1000 mg, 2000 mg or 3000 mg in two divided doses.

Dose	Withdrawal Volume	Volume of Diluent	Infusion Time	Frequency of administration	Total Daily Dose
250 mg	2.5 ml (half 5 ml vial)	100 ml	15 minutes	Twice daily	500 mg/day
500 mg	5 ml (one 5 ml vial)	100 ml	15 minutes	Twice daily	1000 mg/day
1000 mg	10 ml (two 5 ml vials)	100 ml	15 minutes	Twice daily	2000 mg/day
1500 mg	15 ml (three 5 ml vials)	100 ml	15 minutes	Twice daily	3000 mg/day

This medicinal product is for single use only; any unused solution should be discarded. This medicinal product must not be mixed with other medicinal products except those mentioned below. Levetiracetam concentrate was found to be physically compatible and chemically stable when mixed with the following diluents for at least 24 hours and stored in PVC bags at controlled room temperature 15-30°C.

Diluents:

- Sodium chloride (0.9%) injection
- Lactated Ringer's injection
- Dextrose 5% injection

Medicinal product with particulate matter or discolouration should not be used. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

STORAGE

Store below 30°C.

KEEP ALL MEDICINES OUT OF THE REACH OF CHILDREN.

Storage condition and shelf life upon dilution for infusion:

Store at controlled room temperature 15-30°C for 24 hours

Levetiracetam concentrate was found to be physically compatible and chemically stable when mixed with the following diluents for at least 24 hours and stored in PVC bags at controlled room temperature 15-30°C.

Diluents:

- Sodium chloride (0.9%) injection
- Lactated Ringer's injection
- Dextrose 5% injection

SHELF LIFE

24 Months.

After dilution: 24 hours

SUPPLY

Levetiracetam Injection USP 100 mg/ml is a clear colorless solution filled in 5 ml tubular colorless glass vial sealed with light green color flip off Aluminum seal.

Information Revised in October 2020

Manufactured By:
Sun Pharmaceutical Medicare Ltd.
Survey No. 22 & 24, Village: Ujeti,
Post: Baska, Tal. Halol-389 350,
Dist. Panchmahal, Gujarat, India